Abstract
Previous studies have suggested that Interleukin-6 (IL-6) acts as a marker of vasculitis. To determine the role of IL-6 in vasculitis we utilized two models of immune complex induced vascular injury (dermal Arthus and acute pulmonary alveolitis) in IL-6 deficient (IL-6−/−) and IL-6 sufficient (IL-6+/+) mice. Plasma and bronchoalveolar lavage (BAL) levels of IL-6 were elevated in the injured IL-6+/+ mice with acute alveolitis and in the plasma of IL-6+/+ mice with dermal Arthus vasculitis. While, IL-6 levels in IL-6−/− mice were near or below the levels of detection. Histological examination of the intensity of vascular injury response demonstrated no significant differences between IL-6−/− and IL6+/+ mice. More specifically, lung permeability (total protein in the BAL) in the lung injury model in IL-6−/− mice was the same as injured IL-6+/+ mice. As a corollary, assessment of vascular permeability in both models was the same in the IL-6−/− as the IL-6+/+ mice. Quantification of leukocyte influx into the injured tissues in both models also revealed no differences between the IL-6−/− and IL-6+/+ mice. These data demonstrate that while IL-6 is upregulated in acute vascular injury it does not appear to be critical in the development of the vascular inflammatory response.
Similar content being viewed by others
References
Heinrich, P. C., R. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, and F. Schaper. 2003. Review article. Principles of interleukin (IL)-6-type cytokine signaling and its regulation. Biochem. J. 15(374(Pt 1)):1–20.
Tackey, E., P. E. Lipsky, and G. G. Illei. 2004. Rationale for interleukine-6 blockade in systemic lupus erythematosus. Lupus. 13(5):339–343.
Naka, T., N. Nishimoto, and T. Kishimoto. 2002. The paradigm of IL-6: from basic science to medicine. Arthritis Res. 4(Suppl 3):S233–S242.
Sundy, J. S., and B. F. Haynes. 2000. Cytokines and adhesion molecules in the pathogenesis of vasculitis. Curr. Rheumatol. Rep. 2(5):402–410.
Chodorowska, G., and D. Czelej. 2003. Drug-induced hyperalergic vasculitis-activity of selected cytokines and acute phase proteins in plasma. Ann. Univ. Mariae Curie-Sklodowska Sect D, Med. 58(1):43–47.
Ohlsson, S., J. Wieslander, and M. Segelmark. 2004. Circulating cytokine profile in anti-neutrophilic cytoplasmatic autoantibody-associated vasculitis. Prediction of outcome? Mediat. Inflamm. 13(4):275–283.
Nalbant, S., B. Koc, C. Top, Y. Kucukardali, Y. Baykai, M. Danaci, and I. H. Kocer. 2002. Hypersensivity vasculitis and cytokines. Rheumatol. Int. 22(6):244–248.
Goronzy, J. J., and C. M. Weyand. 2002. Cytokines in giant-cell arteritis. Review. Clevel. Clin. J Med. 69(Suppl 2):S1191–S11914.
Muller Kobold, A. C., and C. G. Kallenberg. 1999. Monocyte activation in patients with Wegener’s granulomatosis. Ann. Rheum. Dis. 58(4):237–245.
Tomer, Y., V. Barak, B. Bilburd, and Y. Shoenfeld. 1999. Cytokines in experimental autoimmune vasculitis. Evidence for a Th2 type response. Clin. Exp. Rheumatol. 17(5):521–526.
Shanley, T. P., J. L. Foreback, D. G. Remick, T. R. Ulich, S. L. Kunkel, and P. A. Ward. 1997. Regulatory effects of interleukin-6 in immunoglobulin G immune complex-induced lung injury. Am. J. Pathol. 151(1):193–203.
Morrow, J. D., and M. R. Opp. 2005. Diurnal variation of lipopolysaccharide-induced alterations in sleep and body temperature of interleukin-6-deficient mice. Brain Behav. Immun. 19(1):40–51.
Johnson, K. J., and P. A. Ward. 1974. Acute immunologic pulmonary alveolitis. J. Clin. Invest. 54(2):349–357.
Ward, P. A. 1965. Cochrane CG. Bound complement and immunologic injury of blood vessels. J. Exp. Med. 121:215–234.
Ward, P. A., J. S. Warren, and K. J. Johnson. 1988. Leukocytes, oxidants and tissue injury. Perspect. Crit. Care 1:69–81.
Warren, J. S., K. J. Johnson, and P. A. Ward. 1991. Immunoglobulin and complement mediated immune injury. In: The lung: scientific foundations, R. J. Crystal, J. B. West, P. J. Barnes, N. S. Cherniack and E. R. Weibel eds. Raven, New York, pp. 1939–1949.
Guo, R. F., and P. A. Ward. 2005. Role of C5a in inflammatory responses. Review. Ann. Rev. Immunol. 23:821–852.
Warner, R. L., C. S. Lewis, L. Beltran, E. M. Younkin, J. Varani, and K. J. Johnson. 2001. Role of stromelysin 1 and gelatinase B in experimental acute lung injury. Am. J. Respir. Cell Mol. Biol. 24 (5):537–544.
Warren, J. S. 1991. Disparate roles for TNF in the pathogenesis of acute immune complex alveolitis and dermal vasculitis. Clin. Immunol. Immunopathol. 61(2 Pt 1):249–259.
Speyer, C. L., N. J. Rancilio, S. D. McClintock, J. D.Crawford, H. Gao, J. V. Sarma, and P. A. Ward. 2005. Regulatory effects of estrogen on acute lung inflammation in mice. Am. J. Physiol. Cell Physiol. 288(4):C881–C890.
Riedemann, N. C., T. A. Neff, R. F. Guo, K. D. Bernacki, I. J. Laudes, J. V. Sarma, J. D. Lambris, and P. A. Ward. 2003. Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J. Immunol. 170(1):503–507.
Gennari, R., and J. W. Alexander. 1995. Anti-interleukin-6 antibody treatment improves survival during gut-derived sepsis in a time-dependent manner by enhancing host defense. Crit. Care Med. 23(12):1945–1953.
Remick, D. G., G. Bolgos, S. Copeland, and J. Siddiqui. 2005. Role of interleukin-6 in mortality from and physiologic responses to sepsis. Infect. Immun. 73(5):2751–2757.
Kluger, M. J., W. Kozak, L. R. Leon, and C. A. Conn. 1998. The use of knockout mice to understand the role of cytokines in fever. Clin. Exp. Pharmacol. Physiol. 25(2):141–144.
Sundgren-Andersson, A. K., P. Ostlund, and T. Bartfai. 1996. IL-6 is essential in TNFα induced fever. Am. J. Physiol. 275: R2028–R2034.
Johnston, R. A., I. N. Schwartzman, L. Flynt, and S. A. Shore. 2005. Role of interleukin-6 in murine airway responses to ozone. Am. J. Physiol. Lung Cell Mol. Physiol. 288(2):L390-L397.
Akira, S., H. Isshiki, T. Nakajima, S. Kinoshita, Y. Nishio, S. Natsuka, and T. Kishimoto. 1992. Regulation of expression of the interleukin 6 gene: structure and function of the transcription factor NF-IL6. Ciba Found Symp. 167:47–62.
Kopf, M., G. Le Gros, A. J. Coyle, M. Kosco-Vilbois, and F. Brombacher. 1995. Immune responses of IL-4, IL-5, IL-6 deficient mice. Immunol. Rev. 148:45–69.
Tackey, E., P. E. Lipsky, and G. G. Illei. 2004. Rationale for interleukin-6 blockade in systemic lupus erythematosus. Lupus. 13(5):339–343.
Choy, E. 2004. Clinical experience with inhibition of interleukin-6. Rheum. Dis. Clin. North Am. 30(2):405–415.
Peterson, A. M., and B. K. Pedersen. 2005. The anti-inflammatory effect of exercise. Review. J. Appl. Physiol. 98(4):1154–1162.
Gerlai, R., S. P. Williams, B. Cairns, N. Van Bruggen, P. Moran, A. Shih, I. Caras, H. Sauer, H. S. Phillips, and J. W. Winslow. 1998. Protein targeting in the analysis of learning and memory: a potential alternative to gene targeting. Exp. Brain Res. 123(1–2):24–35.
Hochgeschwender, U., and M. B. Brennan. 1995. Knock out mice rule OK. Nature 375:543.
Gerlai, R. 2001. Gene targeting: technical confounds and potential solutions in behavioral brain research. Behav. Brain Res. 125(1–2):13–21.
Routtenberg, A. 1995. Knockout mouse fault lines. Nature 374:314–315.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work is supported in part by: Pfizer Global Research & Development
Rights and permissions
About this article
Cite this article
McClintock, S.D., Barron, A.G., Olle, E.W. et al. Role of Interleukin-6 in Immune Complex Induced Models of Vascular Injury. Inflammation 29, 154–162 (2005). https://doi.org/10.1007/s10753-006-9011-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-006-9011-1